Madrigal Pharmaceuticals (MDGL) Change in Cash (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Change in Cash data on file, last reported at $28.4 million in Q1 2026.

• On a quarterly basis, Change in Cash fell 66.03% year-over-year to $28.4 million in Q1 2026; TTM through Mar 2026 was $43.5 million, a 110.04% increase from a year earlier, with the FY2025 full-year figure at $98.8 million, up 1835.03% from the prior year.
• Change in Cash for Q1 2026 stood at $28.4 million, up from -$96.9 million in the prior quarter.
• Over the last five years, Change in Cash for MDGL reached as high as $522.6 million in Q1 2024 and fell as low as -$261.9 million in Q3 2024.
• Historically, Change in Cash has averaged $11.5 million across 5 years, with a median of $6.0 million in 2022.
• Across the five-year window, Change in Cash soared 2209.33% in 2022 and slumped 3729.49% in 2023, its largest moves.
• Year by year, Change in Cash stood at $272.2 million in 2022, then sank by 86.09% to $37.9 million in 2023, then tumbled by 450.41% to -$132.7 million in 2024, then grew by 26.95% to -$96.9 million in 2025, then jumped by 129.31% to $28.4 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were $28.4 million in Q1 2026, -$96.9 million in Q4 2025, and $109.5 million in Q3 2025.